Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07080385 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
A Phase 2 study of Autosomal Dominant Hypocalcemia Type 1 (ADH1), sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 5
- Study locations
NCT07080385: Recruiting Phase 2 study of Autosomal Dominant Hypocalcemia Type 1 (ADH1), sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
NCT07080385 is a Phase 2 study of Autosomal Dominant Hypocalcemia Type 1 (ADH1) that is actively recruiting participants, run by Calcilytix Therapeutics, Inc., a BridgeBio company. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07080385, a Phase 2 study of Autosomal Dominant Hypocalcemia Type 1 (ADH1), is actively recruiting participants, sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 5
- Study locations
Study Summary
The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.
Conditions Studied
Interventions
- DRUG Encaleret
Study Locations (5)
Other
- Royal London Hospital - London
- Royal Manchester Children's Hospital - Manchester
Connecticut
- Yale University - New Haven
Florida
- Nemours Children's Health - Jacksonville
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-01-30 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
What NCT07080385 shows while recruiting
NCT07080385 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Autosomal Dominant Hypocalcemia Type 1 (ADH1) appearing as the primary indexed condition, and to 1 intervention - of which Encaleret is the first listed.
NCT07080385 lists 5 locations in 4 states (Other, Connecticut, Florida).
Frequently Asked Questions
What is clinical trial NCT07080385 about?
NCT07080385 is a clinical study titled "Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)". The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.
What is the current status of trial NCT07080385?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2026-01-30. Estimated completion is 2030-12.
What conditions does trial NCT07080385 study?
This clinical trial studies the following conditions: Autosomal Dominant Hypocalcemia Type 1 (ADH1).
What interventions are being tested in trial NCT07080385?
The interventions under investigation include: Encaleret (DRUG).
Who is sponsoring clinical trial NCT07080385?
This trial is sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07080385 being conducted?
This trial has 5 study locations across Connecticut, Florida, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07080385's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI